These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
319 related articles for article (PubMed ID: 32040755)
21. Practical suggestions on intravenous iloprost in Raynaud's phenomenon and digital ulcer secondary to systemic sclerosis: Systematic literature review and expert consensus. Ingegnoli F; Schioppo T; Allanore Y; Caporali R; Colaci M; Distler O; Furst DE; Hunzelmann N; Iannone F; Khanna D; Matucci-Cerinic M Semin Arthritis Rheum; 2019 Feb; 48(4):686-693. PubMed ID: 29706243 [TBL] [Abstract][Full Text] [Related]
22. Systematic literature review to inform the Portuguese recommendations for the management of Raynaud's phenomenon and digital ulcers in systemic sclerosis and other connective tissue diseases. Costa E; Cunha-Santos F; Dourado E; Oliveira D; Falzon L; Romão V; Duarte AC; Cordeiro A; Santiago T; Sepriano A ARP Rheumatol; 2024 Jul; 3(Apr-Jun):128-144. PubMed ID: 38306796 [TBL] [Abstract][Full Text] [Related]
23. Prolonged improvement of Raynaud's phenomenon and scleroderma after recombinant tissue plasminogen activator therapy. Fritzler MJ; Hart DA Arthritis Rheum; 1990 Feb; 33(2):274-6. PubMed ID: 2106327 [TBL] [Abstract][Full Text] [Related]
24. Evidence for the Use of Epoprostenol to Treat Raynaud's Phenomenon With or Without Digital Ulcers. Cruz JE; Ward A; Anthony S; Chang S; Bae HB; Hermes-DeSantis ER Ann Pharmacother; 2016 Dec; 50(12):1060-1067. PubMed ID: 27465880 [TBL] [Abstract][Full Text] [Related]
25. Efficacy of Botulinum Toxin B Injection for Raynaud's Phenomenon and Digital Ulcers in Patients with Systemic Sclerosis. Motegi SI; Uehara A; Yamada K; Sekiguchi A; Fujiwara C; Toki S; Date Y; Nakamura T; Ishikawa O Acta Derm Venereol; 2017 Jul; 97(7):843-850. PubMed ID: 28358168 [TBL] [Abstract][Full Text] [Related]
26. Effect of ketanserin on Raynaud's phenomenon in progressive systemic sclerosis: a double-blind trial. Lukác J; Rovenský J; Tauchmannová H; Zitnan D Drugs Exp Clin Res; 1985; 11(9):659-63. PubMed ID: 3916837 [TBL] [Abstract][Full Text] [Related]
27. Iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis and the quality of life: a new therapeutic protocol. Milio G; Corrado E; Genova C; Amato C; Raimondi F; Almasio PL; Novo S Rheumatology (Oxford); 2006 Aug; 45(8):999-1004. PubMed ID: 16484290 [TBL] [Abstract][Full Text] [Related]
28. Systemic sclerosis therapy with iloprost: a prospective observational study of 30 patients treated for a median of 3 years. Bettoni L; Geri A; Airò P; Danieli E; Cavazzana I; Antonioli C; Chiesa L; Franceschini F; Grottolo A; Zambruni A; Radaeli E; Cattaneo R Clin Rheumatol; 2002 Jun; 21(3):244-50. PubMed ID: 12111631 [TBL] [Abstract][Full Text] [Related]
29. [Therapeutic management of acral manifestations of systemic sclerosis]. Meyer MF; Daigeler A; Lehnhardt M; Steinau HU; Klein HH Med Klin (Munich); 2007 Mar; 102(3):209-18. PubMed ID: 17345017 [TBL] [Abstract][Full Text] [Related]
30. Preventive effect of an oral prostacyclin analog, beraprost sodium, on digital necrosis in systemic sclerosis. French Microcirculation Society Multicenter Group for the Study of Vascular Acrosyndromes. Vayssairat M J Rheumatol; 1999 Oct; 26(10):2173-8. PubMed ID: 10529135 [TBL] [Abstract][Full Text] [Related]
31. [A case of systemic sclerosis in childhood complicated by severe digital ulcers]. Falcini F; Volpi M; Pierattelli M; Taccetti G; Pratesi G; Matucci Cerinich M Pediatr Med Chir; 1984; 6(5):703-7. PubMed ID: 6535137 [TBL] [Abstract][Full Text] [Related]
33. Treatment of ischaemic digital ulcers and prevention of gangrene with intravenous iloprost in systemic sclerosis. Zachariae H; Halkier-Sørensen L; Bjerring P; Heickendorff L Acta Derm Venereol; 1996 May; 76(3):236-8. PubMed ID: 8800308 [TBL] [Abstract][Full Text] [Related]
34. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers. Abou-Raya A; Abou-Raya S; Helmii M J Rheumatol; 2008 Sep; 35(9):1801-8. PubMed ID: 18709692 [TBL] [Abstract][Full Text] [Related]
35. Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon. A randomized, controlled study. Scorza R; Caronni M; Mascagni B; Berruti V; Bazzi S; Micallef E; Arpaia G; Sardina M; Origgi L; Vanoli M Clin Exp Rheumatol; 2001; 19(5):503-8. PubMed ID: 11579708 [TBL] [Abstract][Full Text] [Related]
36. Management of Raynaud's phenomenon and digital ischemic lesions in scleroderma. Hummers LK; Wigley FM Rheum Dis Clin North Am; 2003 May; 29(2):293-313. PubMed ID: 12841296 [TBL] [Abstract][Full Text] [Related]
37. A novel iloprost administration method with portable syringe pump for the treatment of acral ulcers and Raynaud's phenomenon in systemic sclerosis patients. A pilot study (ILOPORTA). Fraticelli P; Martino GP; Murri M; Mattioli M; Gabrielli A Clin Exp Rheumatol; 2017; 35 Suppl 106(4):173-178. PubMed ID: 28869415 [TBL] [Abstract][Full Text] [Related]
39. A 4-week comparison of capillaroscopy changes, healing effect, and cost-effectiveness of botulinum toxin-A vs prostaglandin analog infusion in refractory digital ulcers in systemic sclerosis. Shenavandeh S; Sepaskhah M; Dehghani S; Nazarinia M Clin Rheumatol; 2022 Jan; 41(1):95-104. PubMed ID: 34471968 [TBL] [Abstract][Full Text] [Related]